BIOMAT Database Logo BIOMAT Database Logo

Nandrolone decanoate therapy for anemia in patients on haemodialysis. 1988

H D Balaji, and S Hariharan, and C K Jacob, and M G Kirubakaran, and J C Shastry

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D009277 Nandrolone C18 steroid with androgenic and anabolic properties. It is generally prepared from alkyl ethers of ESTRADIOL to resemble TESTOSTERONE but less one carbon at the 19 position. 19-Nortestosterone,Estrenolone,Norandrostenolone,Nortestosterone,17-Hydroxy-Estr-4-Ene-3-One,17beta-Hydroxy-19-Nor-4-Androsten-3-One,17beta Hydroxy 19 Nor 4 Androsten 3 One
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077603 Nandrolone Decanoate Decanoic acid ester of nandrolone that is used as an anabolic agent to prevent or treat WASTING SYNDROME associated with severe chronic illness or HIV infection (HIV WASTING SYNDROME). It may also be used in the treatment of POSTMENOPAUSAL OSTEOPOROSIS. 17 beta-Hydroxyestr-4-en-3-one 17-decanoate,19-Nortestosterone Decanoate,19-nor-4-Androstene-17 beta-ol-3-one 17-decanoate,Decadurabolin,Decadurobolin,Retabolil,Retabolyl,17 beta Hydroxyestr 4 en 3 one 17 decanoate,19 Nortestosterone Decanoate,19 nor 4 Androstene 17 beta ol 3 one 17 decanoate
D000740 Anemia A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN. Anemias
D045930 Anabolic Agents These compounds stimulate anabolism and inhibit catabolism. They stimulate the development of muscle mass, strength, and power. Anabolic Effect,Anabolic Effects,Agents, Anabolic,Effect, Anabolic,Effects, Anabolic

Related Publications

H D Balaji, and S Hariharan, and C K Jacob, and M G Kirubakaran, and J C Shastry
Effect of nandrolone decanoate on the anemia of chronic hemodialysis patients.
January 1977, Nephron,
H D Balaji, and S Hariharan, and C K Jacob, and M G Kirubakaran, and J C Shastry
Treatment of aplastic anemia with nandrolone decanoate.
December 1970, Blood,
H D Balaji, and S Hariharan, and C K Jacob, and M G Kirubakaran, and J C Shastry
Nandrolone decanoate therapy for patients receiving hemodialysis. A controlled study.
August 1974, Archives of internal medicine,
H D Balaji, and S Hariharan, and C K Jacob, and M G Kirubakaran, and J C Shastry
Nandrolone decanoate is a good alternative for the treatment of anemia in elderly male patients on hemodialysis.
January 1999, Geriatric nephrology and urology,
H D Balaji, and S Hariharan, and C K Jacob, and M G Kirubakaran, and J C Shastry
Use of nandrolone decanoate as an adjuvant for erythropoietin dose reduction in treating anemia in patients on hemodialysis.
January 2005, Nephron. Clinical practice,
H D Balaji, and S Hariharan, and C K Jacob, and M G Kirubakaran, and J C Shastry
Nandrolone decanoate for the treatment of erythropoietin refractory anemia: a case series.
January 2009, Comprehensive therapy,
H D Balaji, and S Hariharan, and C K Jacob, and M G Kirubakaran, and J C Shastry
[Effects on the bones of nandrolone decanoate therapy in postmenopausal osteoporosis].
January 1989, Minerva endocrinologica,
H D Balaji, and S Hariharan, and C K Jacob, and M G Kirubakaran, and J C Shastry
Response of uremic patients to nandrolone decanoate.
July 1975, Archives of internal medicine,
H D Balaji, and S Hariharan, and C K Jacob, and M G Kirubakaran, and J C Shastry
Nandrolone decanoate for men with osteoporosis.
March 1998, American journal of therapeutics,
H D Balaji, and S Hariharan, and C K Jacob, and M G Kirubakaran, and J C Shastry
The effects of nandrolone decanoate on nutritional parameters in hemodialysis patients.
July 2002, Clinical nephrology,
Copied contents to your clipboard!